pmi1is5

Property	Value
?:abstract	OBJECTIVES Widespread global transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), continues. Many questions remain about asymptomatic or atypical infections and transmission dynamics. We used comprehensive contact tracing of the first 2 confirmed patients in Illinois with COVID-19 and serologic SARS-CoV-2 antibody testing to determine whether contacts had evidence of undetected COVID-19. METHODS Contacts were eligible for serologic follow-up if previously tested for COVID-19 during an initial investigation or had greater-risk exposures. Contacts completed a standardized questionnaire during the initial investigation. We classified exposure risk as high, medium, or low based on interactions with 2 index patients and use of personal protective equipment (PPE). Serologic testing used a SARS-CoV-2 spike enzyme-linked immunosorbent assay on serum specimens collected from participants approximately 6 weeks after initial exposure to either index patient. The 2 index patients provided serum specimens throughout their illness. We collected data on demographic, exposure, and epidemiologic characteristics. RESULTS Of 347 contacts, 110 were eligible for serologic follow-up; 59 (17% of all contacts) enrolled. Of these, 53 (90%) were health care personnel and 6 (10%) were community contacts. Seventeen (29%) reported high-risk exposures, 15 (25%) medium-risk, and 27 (46%) low-risk. No participant had evidence of SARS-CoV-2 antibodies. The 2 index patients had antibodies detected at dilutions >1:6400 within 4 weeks after symptom onset. CONCLUSIONS In serologic follow-up of the first 2 known patients in Illinois with COVID-19, we found no secondary transmission among tested contacts. Lack of seroconversion among these contacts adds to our understanding of conditions (ie, use of PPE) under which SARS-CoV-2 infections might not result in transmission and demonstrates that SARS-CoV-2 antibody testing is a useful tool to verify epidemiologic findings.
?:creator	<https://research.tib.eu/covid-19/entity/McPherson%2C_Tristan_D%3B_Ghinai%2C_Isaac%3B_Binder%2C_Alison_M%3B_Freeman%2C_Brandi_D%3B_Hoskin_Snelling%2C_Chantel%3B_Hunter%2C_Jennifer_C%3B_Anderson%2C_Kristin_M%3B_Davenport%2C_Polly%3B_Rudd%2C_Deborah_L%3B_Zafer%2C_Mujeeb%3B_Christiansen%2C_Demian%3B_Joshi%2C_Kiran%3B_Rubin%2C_Rachel%3B_Black%2C_Stephanie_R%3B_Fricchione%2C_Marielle_J%3B_Pacilli%2C_Massimo%3B_Walblay%2C_Kelly_A%3B_Korpics%2C_Jacqueline%3B_Moeller%2C_Darcie%3B_Quartey-Kumapley%2C_Pearl%3B_Wang%2C_Chen%3B_Charles%2C_E_Matt%3B_Kauerauf%2C_Judy%3B_Patel%2C_Megan_T%3B_Disari%2C_Vishal_S%3B_Fischer%2C_Marc%3B_Jacobs%2C_Max_W%3B_Lester%2C_Sandra_N%3B_Midgley%2C_Claire_M%3B_Rasheed%2C_Mohammed_Ata_Ur%3B_Reese%2C_Heather_E%3B_Verani%2C_Jennifer_R%3B_Wallace%2C_Megan%3B_Watson%2C_John_T%3B_Thornburg%2C_Natalie_J%3B_Layden%2C_Jennifer_E%3B_Kirking%2C_Hannah_L>
?:doi	<https://research.tib.eu/covid-19/entity/10.1177/0033354920966064>
?:doi	10.1177/0033354920966064
?:journal	Public_health_reports
?:license	unk
?:pmid	<https://research.tib.eu/covid-19/entity/33108976.0>
?:pmid	33108976.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	Medline
?:title	Lack of Serologic Evidence of Infection Among Health Care Personnel and Other Contacts of First 2 Confirmed Patients With COVID-19 in Illinois, 2020.
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-10-27

Property

Value

?:abstract

OBJECTIVES Widespread global transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), continues. Many questions remain about asymptomatic or atypical infections and transmission dynamics. We used comprehensive contact tracing of the first 2 confirmed patients in Illinois with COVID-19 and serologic SARS-CoV-2 antibody testing to determine whether contacts had evidence of undetected COVID-19. METHODS Contacts were eligible for serologic follow-up if previously tested for COVID-19 during an initial investigation or had greater-risk exposures. Contacts completed a standardized questionnaire during the initial investigation. We classified exposure risk as high, medium, or low based on interactions with 2 index patients and use of personal protective equipment (PPE). Serologic testing used a SARS-CoV-2 spike enzyme-linked immunosorbent assay on serum specimens collected from participants approximately 6 weeks after initial exposure to either index patient. The 2 index patients provided serum specimens throughout their illness. We collected data on demographic, exposure, and epidemiologic characteristics. RESULTS Of 347 contacts, 110 were eligible for serologic follow-up; 59 (17% of all contacts) enrolled. Of these, 53 (90%) were health care personnel and 6 (10%) were community contacts. Seventeen (29%) reported high-risk exposures, 15 (25%) medium-risk, and 27 (46%) low-risk. No participant had evidence of SARS-CoV-2 antibodies. The 2 index patients had antibodies detected at dilutions >1:6400 within 4 weeks after symptom onset. CONCLUSIONS In serologic follow-up of the first 2 known patients in Illinois with COVID-19, we found no secondary transmission among tested contacts. Lack of seroconversion among these contacts adds to our understanding of conditions (ie, use of PPE) under which SARS-CoV-2 infections might not result in transmission and demonstrates that SARS-CoV-2 antibody testing is a useful tool to verify epidemiologic findings.

?:creator